Status of radiation treatment of prostate cancer at Stanford University.

Over 900 patients have been treated with radiation therapy in the 30-year Stanford prostate study. Overall survival, i.e., scoring death due to all causes, was 45%, 35%, 33%, 20%, and 10% for Stanford stages T0, T1, T2, T3, and T4 (nominal stages A, B1, B2, C) at 15 years; lymph node status was unknown. Disease-specific survival at 15 years was 85%, 64%, 45%, 33%, and 15%, respectively, for the same patients. In 141 patients with restricted nodular disease (lymph node status unknown) equal to or less than one-half of one lobe involved (stage B1), the 15-year overall survival was 50% and identical to the expected survival of an age-matched cohort of males. Potency was preserved in 86% of the patients at 15 months posttreatment, and 50% of the patients maintained erectile potency for 7 years posttherapy. Other sequelae and complications are analyzed. The incidence of second neoplasms did not exceed expectations for an age-matched population.